Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Gynecologic 1Genitourinary 1

Conditions

Neoplasms 1

Interventions

trastuzumab deruxtecan 1pembrolizumab 1margetuximab 1lenvatinib 1larotrectinib 1atezolizumab 1Trastuzumab 1Pemetrexed 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × lenvatinib × Tumor-Agnostic × Clear all
NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Eisai Inc.

Phase 1/2 Completed
357 enrolled 28 charts 1 FDA
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡